
Sun Pharmaceuticals Industries’ (SUNP IN) acquisition of Checkpoint Therapeutics (CKPT) would give SUNP access to a USFDA-approved novel drug asset, Cosibelimab (approved in December 2024), meant to treat locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC and mCSCC). Through this acquisition, SUNP intends to deepen its presence in the skin cancer segment; SUNP’s existing portfolio in this space includes Levulan and Odomzo, having filed Nidlegy for melanoma
Recent Comments